Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functiona…
| Periodo | 2026-08 | 2026-05 | 2026-02 | 2025-11 |
|---|---|---|---|---|
| Real | — | $4.26 | $3.36 | $3.06 |
| Estimado | — | $4.16 | $7.15 | $4.07 |
| Sorpresa | — | +2.4% | -53.0% | -24.8% |
| Métrica | NSIS-B.CO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 53.9% | 27.7% | +26.2% |
| Operating Margin | 19.6% | 5.8% | +13.9% |
| Net Margin | 14.0% | 2.7% | +11.3% |
| FCF Margin | 19.5% | 3.5% | +16.0% |
| ROE | 5.4% | -0.1% | +5.5% |
| ROA | 3.6% | -1.6% | +5.1% |
| Current Ratio | 0.72 | 2.01 | -1.29 |
| Debt / Equity | 0.12 | 0.32 | -0.20 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 3.6% | — |
| ✓Flujo de caja operativo positivo | €1.2B | €1.0B |
| ✓Rentabilidad sobre activos al alza | 3.6% | 2.0% |
| ✓Caja operativa/activos supera al ROA | 7.5% | ROA 3.6% |
| ✓Menos deuda a largo plazo | 8.0% | 10.1% |
| ✗Mejor liquidez (ratio corriente) | 0.72 | 1.73 |
| ✗Sin aumentar el nº de acciones | 467M | 456M |
| ✓Margen bruto al alza | 53.9% | 47.2% |
| ✓Rotación de activos al alza | 0.25 | 0.25 |
| Calidad del negocio | FY25 |
|---|---|
| ✓Margen FCF > 10 % | 19.5% |
| ✗ROCE > 10 % | 6.0% |
| ✗Ventas > 5 %/año (3 años) | -38.1% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 21.0% |
NOVOZYMES A/S cotiza a 454.80 DKK y tiene una capitalización bursátil de DKK 212.1B. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Materiales básicos